Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

2.18
+0.06002.83%
Post-market: 2.220.0400+1.83%19:34 EDT
Volume:55.70K
Turnover:120.08K
Market Cap:4.00M
PE:-0.08
High:2.23
Open:2.16
Low:2.05
Close:2.12
52wk High:44.10
52wk Low:1.50
Shares:1.84M
Float Shares:1.65M
Volume Ratio:0.17
T/O Rate:3.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-18.37%
PB:0.54
PE(LYR):-0.03

Loading ...

Press Release: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

Dow Jones
·
May 15

HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia

TIPRANKS
·
May 14

BRIEF-HCW Biologics Discovers That HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies

Reuters
·
May 14

HCW Biologics Inc - Expects to Complete Ind-Enabling Studies in H2 2027 and File Ind Application for HCW11-040

THOMSON REUTERS
·
May 14

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

GlobeNewswire
·
May 14

HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

GlobeNewswire
·
May 01

HCW Biologics Inc - Agreement to Commence on or About May 1, 2026, Subject to Public Offering Close - SEC Filing

THOMSON REUTERS
·
Apr 30

HCW Biologics Inc - on April 25, Co to Enter $2.5 Mln Marketing Consulting Agreement With I.r. Agency Llc - SEC Filing

THOMSON REUTERS
·
Apr 30

HCW Biologics to file IND for HCW11-018b in first half of 2027

TIPRANKS
·
Apr 27

BRIEF-Hcw Biologics Delivers A Major Update For Its T-Cell Engager Program Revealing Mechanism Of Action

Reuters
·
Apr 27

HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors

GlobeNewswire
·
Apr 27

HCW Biologics Lowers Shareholder Meeting Quorum Requirement

TIPRANKS
·
Apr 17

HCW Biologics lowers shareholder meeting quorum to 33.3% voting power

Reuters
·
Apr 17

HCW Biologics Q4 revenue drops sharply on license suspension

Reuters
·
Apr 01

HCW Biologics FY25 net loss narrows to $6.5 million; revenue drops to $54,232

Reuters
·
Apr 01

HCW Biologics, Inc Q4 Basic EPS USD -1.02

THOMSON REUTERS
·
Apr 01

Press Release: HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

Dow Jones
·
Apr 01

Analysts Offer Insights on Healthcare Companies: XOMA Royalty Corporation (XOMA) and HCW Biologics (HCWB)

TIPRANKS
·
Mar 19

3 Penny Stocks to Watch Now, 3/17/26

TIPRANKS
·
Mar 17

BRIEF-Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic

Reuters
·
Mar 17